Bulletin
Investor Alert

New York Markets Open in:

Sept. 22, 2022, 6:04 p.m. EDT

Pfizer Stock up on Late-Stage Trials for New Vaccine

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Pfizer Inc. (PFE)
  • X
    GSK PLC ADR (GSK)

or Cancel Already have a watchlist? Log In

Sep 22, 2022 (PressReach.com via COMTEX) -- Pfizer stock responds well to developments, trading at PFE +0.22% to $46.25 premarket on September 15.

Pfizer /zigman2/quotes/202877789/composite PFE +1.90% will be seeking FDA approval given the Pan-meningococcal vaccine is superior to Trumenba, and GSK’s Menveo is in testing. Pfizer /zigman2/quotes/202877789/composite PFE +1.90% said that its pentavalent meningococcal vaccination (MenABCWY), which met the primary and secondary goals of a phase 3 trial in healthy individuals aged 10 to 25 years, was as effective as its own meningococcal illness vaccine, Trumenba, and GSK’s /zigman2/quotes/209463850/composite GSK +1.27% Menveo.

Any illness brought on by the Neisseria meningitidis bacteria is referred to as a meningococcal disease . According to the U.S. CDC, these disorders include blood infections and meningitis, which affect the lining of the brain and spinal cord. They are frequently fatal.

In a press release on September 15, Pfizer stated that the MenACWY and MenB vaccines are currently licensed separately and that no one vaccination is available to help protect against the five serogroups--serogroups A, B, C, W, and Y--which cause the majority of invasive meningococcal illness.

Pfizer’s Group B Strep Vaccine Gets FDA Breakthrough Designation

Menveo is licensed for MenACWY, and Trumenba is for meningitis B. In the trial, participants either got two doses of MenABCWY or two doses of Trumenba with one dose of Menveo, two approved vaccinations . The business reported that in comparison to two doses of Trumenba and one dosage of Menveo, data indicated non-inferiority for all five serogroups following two doses of MenABCWY. In addition, Pfizer claimed that a single dose of MenABCWY compared to a single dose of Menveo fulfilled the non-inferiority criteria for serogroups A, C, W, and Y.

The proportion of patients who had immune responses that were four times greater following either one or two doses of MenABCWY for serogroups A, C, W, and Y was observed to be higher among individuals who had not previously received a meningococcal vaccine than after one dose of Menveo, the company noted.

According to Pfizer, more individuals showed a 4-fold increase in immune responses to all four serogroup B strains after receiving two doses of MenABCWY than after receiving two doses of Trumenba. According to the manufacturer, MenABCWY was well accepted and had a safety profile similar to that of approved vaccinations.

In order to get the vaccine approved, Pfizer intends to submit a biologics license application to the American Food and Drug Administration in Q4 2022. If licensed, MenABCWY would offer the most comprehensive serogroup coverage of any meningococcal vaccine and aid in streamlining the meningococcal vaccination schedule.

PFE +0.22% to $46.25 premarket on September 15

Featured Image - Megapixl (C) Vladsseven

Please See Disclaimer

Visit PressReach.com To Get More Articles Like This

Author: Jowi Kwasu
Market Jar Media Inc.
info@marketjar.com
#170 - 422 Richards Street
Vancouver, BC, Canada
V6B 2Z4
1.800.340.9767

COMTEX_415063208/2810/2022-09-22T18:04:10

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

/zigman2/quotes/202877789/composite
US : U.S.: NYSE
$ 51.08
+0.95 +1.90%
Volume: 23.59M
Dec. 1, 2022 4:03p
P/E Ratio
9.84
Dividend Yield
3.13%
Market Cap
$281.40 billion
Rev. per Employee
$1.26M
loading...
/zigman2/quotes/202877789/composite
US : U.S.: NYSE
$ 51.08
+0.95 +1.90%
Volume: 23.59M
Dec. 1, 2022 4:03p
P/E Ratio
9.84
Dividend Yield
3.13%
Market Cap
$281.40 billion
Rev. per Employee
$1.26M
loading...
/zigman2/quotes/209463850/composite
US : U.S.: NYSE
$ 35.03
+0.44 +1.27%
Volume: 3.87M
Dec. 1, 2022 4:00p
P/E Ratio
4.30
Dividend Yield
5.71%
Market Cap
$67.74 billion
Rev. per Employee
$486,707
loading...

This Story has 0 Comments
Be the first to comment

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.